The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy
Yi-Yun Sheng,1 Qing Zhu,2 Qian-Bin Dai,2 Yu-Jie Gao,2 Yun-Xue Bai,2 Mei-Fang Liu2 1Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Clinical Laboratory, The First Affiliated Hospital, Ji...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-prognostic-value-of-systemic-immune-inflammation-index-supporting--peer-reviewed-fulltext-article-IJGM |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169115403091968 |
|---|---|
| author | Sheng YY Zhu Q Dai QB Gao YJ Bai YX Liu MF |
| author_facet | Sheng YY Zhu Q Dai QB Gao YJ Bai YX Liu MF |
| author_sort | Sheng YY |
| collection | DOAJ |
| description | Yi-Yun Sheng,1 Qing Zhu,2 Qian-Bin Dai,2 Yu-Jie Gao,2 Yun-Xue Bai,2 Mei-Fang Liu2 1Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of ChinaCorrespondence: Mei-Fang Liu, Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China, Tel +86 0791 86319430, Fax +86 0791 88692272, Email mfliu922@163.comPurpose: This study aimed to examine the association between the systemic immune-inflammation index (SII) (ie, neutrophil count × platelet count/lymphocyte count), the age-adjusted Charlson comorbidity index (ACCI), and overall survival (OS) in non-small cell lung cancer (NSCLC) patients undergoing first-line platinum-based chemotherapy (PBC), with a particular emphasis on the role of SII in supporting ACCI.Patients and Methods: This retrospective study enrolled 353 cases treated between July 2013 and November 2020. Mann–Whitney U-test and Kruskal–Wallis test were employed to compare parameters between high and low SII groups. The cut-off values for SII and ACCI were determined using the X-tile software. Prognostic significance was evaluated through the utilization of Kaplan-Meier curves and Cox regression analysis.Results: In a univariate Cox regression analysis, sex, age, TNM, lymph node, therapy, SII, and ACCI were associated with OS. After adjusting for confounders in the multivariate analysis, TNM, SII, and ACCI remained independent prognostic factors for OS. Furthermore, within the ACCI subgroups (ACCI< 5 or ACCI≥ 5), a high SII was significantly associated with an increased risk of death. Patients with both a high ACCI and a high SII had the highest risk of death (p < 0.001), with a loss of approximately ten months of survival during the first three years after treatment.Conclusion: SII was proven to be valuable in predicting OS and, when complemented by ACCI, can help tailor prognostic assessment and treatment strategies in assessing the survival of NSCLC patients with first-line PBC.Keywords: non-small cell lung cancer, platinum-based chemotherapy, systemic immune-inflammation index, age-adjusted Charlson comorbidity index, prognostic, overall survival |
| format | Article |
| id | doaj-art-e1fbe8b3fce145c2929763f3e38e2ddd |
| institution | OA Journals |
| issn | 1178-7074 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj-art-e1fbe8b3fce145c2929763f3e38e2ddd2025-08-20T02:20:48ZengDove Medical PressInternational Journal of General Medicine1178-70742024-12-01Volume 175837584898045The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based ChemotherapySheng YYZhu QDai QBGao YJBai YXLiu MFYi-Yun Sheng,1 Qing Zhu,2 Qian-Bin Dai,2 Yu-Jie Gao,2 Yun-Xue Bai,2 Mei-Fang Liu2 1Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of ChinaCorrespondence: Mei-Fang Liu, Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China, Tel +86 0791 86319430, Fax +86 0791 88692272, Email mfliu922@163.comPurpose: This study aimed to examine the association between the systemic immune-inflammation index (SII) (ie, neutrophil count × platelet count/lymphocyte count), the age-adjusted Charlson comorbidity index (ACCI), and overall survival (OS) in non-small cell lung cancer (NSCLC) patients undergoing first-line platinum-based chemotherapy (PBC), with a particular emphasis on the role of SII in supporting ACCI.Patients and Methods: This retrospective study enrolled 353 cases treated between July 2013 and November 2020. Mann–Whitney U-test and Kruskal–Wallis test were employed to compare parameters between high and low SII groups. The cut-off values for SII and ACCI were determined using the X-tile software. Prognostic significance was evaluated through the utilization of Kaplan-Meier curves and Cox regression analysis.Results: In a univariate Cox regression analysis, sex, age, TNM, lymph node, therapy, SII, and ACCI were associated with OS. After adjusting for confounders in the multivariate analysis, TNM, SII, and ACCI remained independent prognostic factors for OS. Furthermore, within the ACCI subgroups (ACCI< 5 or ACCI≥ 5), a high SII was significantly associated with an increased risk of death. Patients with both a high ACCI and a high SII had the highest risk of death (p < 0.001), with a loss of approximately ten months of survival during the first three years after treatment.Conclusion: SII was proven to be valuable in predicting OS and, when complemented by ACCI, can help tailor prognostic assessment and treatment strategies in assessing the survival of NSCLC patients with first-line PBC.Keywords: non-small cell lung cancer, platinum-based chemotherapy, systemic immune-inflammation index, age-adjusted Charlson comorbidity index, prognostic, overall survivalhttps://www.dovepress.com/the-prognostic-value-of-systemic-immune-inflammation-index-supporting--peer-reviewed-fulltext-article-IJGMnon-small cell lung cancerplatinum-based chemotherapysystemic immune-inflammation indexage-adjusted charlson comorbidity indexprognosticoverall survival |
| spellingShingle | Sheng YY Zhu Q Dai QB Gao YJ Bai YX Liu MF The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy International Journal of General Medicine non-small cell lung cancer platinum-based chemotherapy systemic immune-inflammation index age-adjusted charlson comorbidity index prognostic overall survival |
| title | The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy |
| title_full | The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy |
| title_fullStr | The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy |
| title_full_unstemmed | The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy |
| title_short | The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy |
| title_sort | prognostic value of systemic immune inflammation index supporting age adjusted charlson comorbidity index in non small cell lung cancer patients with first line platinum based chemotherapy |
| topic | non-small cell lung cancer platinum-based chemotherapy systemic immune-inflammation index age-adjusted charlson comorbidity index prognostic overall survival |
| url | https://www.dovepress.com/the-prognostic-value-of-systemic-immune-inflammation-index-supporting--peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT shengyy theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT zhuq theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT daiqb theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT gaoyj theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT baiyx theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT liumf theprognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT shengyy prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT zhuq prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT daiqb prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT gaoyj prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT baiyx prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy AT liumf prognosticvalueofsystemicimmuneinflammationindexsupportingageadjustedcharlsoncomorbidityindexinnonsmallcelllungcancerpatientswithfirstlineplatinumbasedchemotherapy |